$ISRG

Brosius Mark sold $17K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 48 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $357.10 ($347.66–$365.79) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brosius Mark
Published Sep 11, 2026, 10:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The disclosed sale is small and pre‑arranged, offering little new insight for traders.

02

Market read

Routine insider sell with negligible market impact.

03

What to watch

The sale was executed under a pre‑arranged 10b5‑1 plan, reducing the likelihood of information‑based motives.

Relevance 2/10Novelty 4/10Timing: filing date 2026‑09‑11

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Mark Brosius, EVP & Chief Mfg and Supply Chain at Intuitive Surgical, sold 48 shares for $17,140 via a 10b5‑1 plan.

Expected impact

No material price impact expected.

Evidence & confidence

The sale size is small relative to market cap and disclosed via a routine 10b5‑1 plan.

Market effects

None; the transaction is company‑specific and does not affect the broader medical device sector.

None; limited to US investors tracking insider activity.

Minimal.

Counterpoint

If the insider had a larger stake, the sale could signal concerns, but at this scale it is routine.

Key entities

  • Intuitive Surgical Inc.

    Medical device maker (ticker ISRG).

  • Mark Brosius

    EVP & Chief Manufacturing and Supply Chain at Intuitive Surgical.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for da Vinci 5 cardiac procedures

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci 5 system in cardiac procedures, including coronary artery bypasses and thoracoscopic cardiotomy. The company aims to expand its robotic-assisted cardiac surgery offerings in Europe, with a dedicated team and partnerships with select centers. ISRG previously received FDA clearance for cardiac use in January.

$ISRGHighAI 8/10

Intuitive Surgical Gains CE Mark for Cardiac Robotics

Intuitive Surgical received CE mark approval for its da Vinci surgical robot to perform cardiac procedures in adults, including minimally invasive coronary artery bypass. This approval allows Intuitive to compete with rivals Medtronic and Johnson & Johnson in the surgical robotics space. The company aims to expand its cardiac surgery offerings globally, following FDA clearance for cardiovascular procedures in January.

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.